Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 20486856)

1.

The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.

Einav S, Sobol HD, Gehrig E, Glenn JS.

J Infect Dis. 2010 Jul 1;202(1):65-74. doi: 10.1086/653080.

2.

Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.

Mathy JE, Ma S, Compton T, Lin K.

Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. doi: 10.1128/AAC.00498-08. Epub 2008 Jun 30.

3.

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Wyles DL, Kaihara KA, Schooley RT.

Antimicrob Agents Chemother. 2008 May;52(5):1862-4. doi: 10.1128/AAC.01208-07. Epub 2008 Mar 10.

4.

The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.

McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I.

Antimicrob Agents Chemother. 2008 May;52(5):1604-12. doi: 10.1128/AAC.01317-07. Epub 2008 Feb 19.

5.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
6.
7.

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J.

Antimicrob Agents Chemother. 2009 Mar;53(3):967-76. doi: 10.1128/AAC.00939-08. Epub 2008 Dec 22.

8.

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.

Brown NA.

Expert Opin Investig Drugs. 2009 Jun;18(6):709-25. doi: 10.1517/13543780902854194 . Review.

PMID:
19426125
9.

New HCV therapies on the horizon.

Vermehren J, Sarrazin C.

Clin Microbiol Infect. 2011 Feb;17(2):122-34. doi: 10.1111/j.1469-0691.2010.03430.x. Review.

10.

Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.

Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F.

Antimicrob Agents Chemother. 2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12. Epub 2012 Dec 28.

11.

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.

Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J.

Hepatology. 2009 Jul;50(1):6-16. doi: 10.1002/hep.22916.

PMID:
19437494
12.

Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.

Gu Z, Graci JD, Lahser FC, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM.

Antimicrob Agents Chemother. 2013 Jul;57(7):3250-61. doi: 10.1128/AAC.00527-13. Epub 2013 Apr 29.

13.

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.

Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefèbvre S, Thauvette L, Gauthier J, Goulet S, Poupart MA, Beaulieu PL.

J Biol Chem. 2005 Nov 25;280(47):39260-7. Epub 2005 Sep 27.

15.

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, Cellucci A, Forte E, Incitti I, Orsatti L, Koch U, De Francesco R, Olsen DB, Carroll SS, Migliaccio G.

J Virol. 2004 Jan;78(2):938-46.

16.

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL.

J Infect Dis. 2012 Feb 15;205(4):656-62. doi: 10.1093/infdis/jir802.

17.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

18.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
19.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

Chase R, Skelton A, Xia E, Curry S, Liu S, McMonagle P, Huang HC, Tong X.

Antiviral Res. 2009 Nov;84(2):178-84. doi: 10.1016/j.antiviral.2009.09.003. Epub 2009 Sep 10.

PMID:
19747948
20.

A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.

Katsume A, Tokunaga Y, Hirata Y, Munakata T, Saito M, Hayashi H, Okamoto K, Ohmori Y, Kusanagi I, Fujiwara S, Tsukuda T, Aoki Y, Klumpp K, Tsukiyama-Kohara K, El-Gohary A, Sudoh M, Kohara M.

Gastroenterology. 2013 Oct;145(4):865-73. doi: 10.1053/j.gastro.2013.06.012. Epub 2013 Jun 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk